Use of infliximab and other biologics in Behçet disease
Article first published online: 23 JAN 2014
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 44, Issue 1, pages 96–100, January 2014
How to Cite
Li, J., Fernando, S. and Herkes, G. (2014), Use of infliximab and other biologics in Behçet disease. Internal Medicine Journal, 44: 96–100. doi: 10.1111/imj.12297
Conflict of interest: None.
- Issue published online: 23 JAN 2014
- Article first published online: 23 JAN 2014
- Manuscript Accepted: 14 JUL 2013
- Manuscript Received: 5 MAR 2013
- Behçet disease;
Behçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro-Behçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long-term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro-Behçet disease.